← 返回

CAR-T 治疗血液肿瘤与实体瘤的当前进展与挑战

英文原题:Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors.

查看英文原题

Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors.

PubMed 2025/06/27(内容时间) Immunotargets Ther Q2 · IF 4.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

尽管 CAR-T 疗法已经彻底改变了某些血液系统恶性肿瘤的治疗,但将其成功扩展到实体瘤仍面临重大障碍。持续的研究努力,聚焦于提高 CAR-T 细胞的疗效、安全性和可及性,对于在广泛癌症类型中充分释放这种创新免疫治疗方法的潜力至关重要。

研究思路结论见上方概要

嵌合抗原受体(CAR)T细胞疗法已经彻底改变了难治性血液系统恶性肿瘤的治疗,但将其成功扩展到实体瘤仍面临重大挑战。本综述旨在全面概述CAR-T 疗法在血液系统恶性肿瘤和实体瘤中的当前格局和未来前景。

进行了全面的文献检索,以识别有关CAR-T 疗法在各种血液系统恶性肿瘤和实体瘤中的相关临床前和临床研究以及综述文章。对收集到的信息进行了综合,以讨论在这些情况下CAR-T 疗法的当前应用、挑战和改进策略。

CAR-T 疗法在治疗某些血液系统恶性肿瘤(如 B 细胞淋巴瘤、白血病和多发性骨髓瘤)方面已展现出令人瞩目的临床结局。然而,由于肿瘤异质性、免疫抑制微环境以及脱靶毒性等多种障碍,CAR-T 细胞在实体瘤中的疗效一直受限。克服这些挑战的策略涉及先进的 CAR 设计、联合疗法,以及 CAR-T 细胞制造和工程化的新方法。

展开英文摘要原文

A thorough literature search was conducted to identify relevant preclinical and clinical studies, as well as review articles, focusing on CAR-T therapy in various hematological malignancies and solid tumors. The collected information was synthesized to discuss the current applications, challenges, and strategies for improving CAR-T therapy in these settings.

CAR-T therapy has demonstrated impressive clinical outcomes in treating certain hematological malignancies, such as B-cell lymphoma, leukemia, and multiple myeloma. However, the efficacy of CAR-T cells in solid tumors has been limited due to various obstacles, including tumor heterogeneity, immunosuppressive microenvironment, and off-tumor toxicities. Strategies to overcome these challenges involve advanced CAR designs, combination therapies, and novel approaches to CAR-T cell manufacturing and engineering.

While CAR-T therapy has revolutionized the treatment of some hematological malignancies, significant hurdles remain in extending its success to solid tumors. Continued research efforts focusing on improving CAR-T cell efficacy, safety, and accessibility will be crucial in unlocking the full potential of this innovative immunotherapeutic approach across a broad spectrum of cancer types.

论文信息

作者
Zhang G、Bai M、Du H、Yuan Y、Wang Y、Fan W、Zhu H、Wu D
第一作者单位
Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, People's Republic of China.China
通讯作者单位
Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, People's Republic of China.China
文献类型
综述
期刊
ImmunoTargets and therapy2025
原文标识
PubMed 40599347 · DOI 10.2147/ITT.S519616